How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

264 results for

Adamantane

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One

data but these mutations are likely to result in reduced antiviral efficacy of Oseltamivir and the adamantanes against H1N1. Furthermore, amantadine treatment of influenza frequently results in the rapid development of amantadine resistance in both H1N1 and H2N3 viruses, resulting in continued virus replication, thus, making this drug less than ideal for treating influenza. Currently, there is limited adamantane resistant H1N1 but widespread adamantane resistant in H3N2. H3N2 and influenza B remain (...) sensitive to Oseltamivir. The adamantanes have no activity against influenza B. The emergence of resistance poses difficulties for the treatment of influenza in children less than one but oseltamivir represents at present the optimal choice for treating such children. Therefore, this protocol will assess the effect of oral Oseltamivir at doses recommended by the WHO to see if they are applicable to Thai children. Study Design Go to Layout table for study information Study Type : Interventional (Clinical

2012 Clinical Trials

182. Adenosine A2A receptor modulates vascular response in soluble epoxide hydrolase-null mice through CYP-epoxygenases and PPARγ (PubMed)

-adamantan-1-yl-ureido) dodecanoic acid (AUDA; 10 μM) or trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (t-AUCB, sEH-inhibitors; 10(-5) M), and T0070907 (PPARγ-antagonist; 10(-7) M). In sEH(-/-) mice, ACh response was not different from sEH(+/+) (P > 0.05), and l-NAME blocked ACh-responses in both sEH(-/-) and sEH(+/+) mice (P < 0.05). NECA (10(-6) M)-induced relaxation was higher in sEH(-/-) (+12.94 ± 3.2%) vs. sEH(+/+) mice (-5.35 ± 5.2%); however, it was blocked by ZM-241385 (-22.42

Full Text available with Trip Pro

2012 American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

183. Comment on: Rizzo et al. Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of Dipeptidyl Peptidase-IV Inhibition. Diabetes Care 2012;35:2076–2082 (PubMed)

inhibition. Diabetes Care 2012;35:2076-2082. e12 10.2337/dc12-1218 Devries J Hans JH eng Letter Comment United States Diabetes Care 7805975 0149-5992 0 Blood Glucose 0 Dipeptidyl-Peptidase IV Inhibitors 0 Nitriles 0 Pyrazines 0 Pyrrolidines 0 Triazoles PJY633525U Adamantane IM Diabetes Care. 2012 Oct;35(10):2076-82 22688551 Diabetes Care. 2013 Jan;36(1):e13 23264296 Adamantane analogs & derivatives Blood Glucose drug effects Diabetes Mellitus, Type 2 drug therapy Dipeptidyl-Peptidase IV Inhibitors

Full Text available with Trip Pro

2012 Diabetes Care

184. Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study. (PubMed)

Pharmacokinetics and safety of coadministered oseltamivir and rimantadine in healthy volunteers: an open-label, multiple-dose, randomized, crossover study. Preclinical data suggest increased antiviral activity and less viral resistance when neuraminidase inhibitors and adamantanes are used in combination to harness the complementary effects of their different mechanisms of action. Healthy volunteers were randomized to 5-day oral treatment with oseltamivir 75 mg or rimantadine 100 mg twice daily

2012 Journal of clinical pharmacology Controlled trial quality: uncertain

185. MultiDrug-Resistant 2009 Pandemic Influenza A(H1N1) Viruses Maintain Fitness and Transmissibility in Ferrets. (PubMed)

appeared containing resistance to neuraminidase inhibitors and the adamantanes, but the ability of these viruses to replicate, transmit, and cause disease in mammalian hosts has not been fully characterized.Two pretreatment wild-type viruses and 2 posttreatment multidrug-resistant viruses containing the neuraminidase H275Y mutation collected from immunocompromised patients infected with pandemic influenza H1N1 were tested for viral fitness, pathogenicity, and transmissibility in ferrets.The

Full Text available with Trip Pro

2011 Journal of Infectious Diseases

186. Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir-Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System. (PubMed)

Zanamivir, at 600 mg Twice Daily, Inhibits Oseltamivir-Resistant 2009 pandemic H1N1 Influenza Virus in an in vitro Hollow Fiber Infection Model System. In 2009, a novel H1N1 influenza A virus emerged and spread worldwide, initiating a pandemic. Various isolates obtained from disparate parts of the world were shown to be uniformly resistant to the adamantanes but sensitive to the neuraminidase inhibitors oseltamivir and zanamivir. Over time, resistance to oseltamivir became more prevalent among

Full Text available with Trip Pro

2011 Antimicrobial Agents and Chemotherapy

187. Safety Study of Single Administration Intravenous Treatment for Influenza

) the increased frequency of resistance to approved forms of therapy for influenza (eg, the adamantane derivatives and, more recently, the NA inhibitor, oseltamivir). AVI-7100 is an experimental phosphorodiamidate morpholino antisense oligomers with positive charges on selected subunits (PMOplus™). AVI-7100 specifically targets viral messenger RNA sequences. The present study is designed to characterize the safety, tolerability and pharmacokinetics of escalating single-administration doses of AVI-7100

2011 Clinical Trials

188. DPP-4 Inhibitors: Impact on glycemic control and cardiovascular risk factors (PubMed)

Dipeptides 0 Dipeptidyl-Peptidase IV Inhibitors 0 Nitriles 0 Pyrrolidines 9GB927LAJW saxagliptin I6B4B2U96P Vildagliptin PJY633525U Adamantane IM Adamantane analogs & derivatives therapeutic use Cardiovascular Diseases prevention & control Dipeptides therapeutic use Dipeptidyl-Peptidase IV Inhibitors therapeutic use Humans Nitriles therapeutic use Pyrrolidines therapeutic use Risk Factors Vildagliptin 2011 4 29 6 0 2011 5 6 6 0 2011 7 2 6 0 ppublish 21525468 34/Supplement_2/S276 10.2337/dc11-s229

Full Text available with Trip Pro

2011 Diabetes Care

189. Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes (PubMed)

trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (tAUCB) also reduced renal inflammation and injury in diabetic WT mice. Furthermore, inhibition of HO with stannous mesoporphyrin negated the reno-protective effects of tAUCB or Ephx2 KO during diabetes. These data demonstrate that Ephx2 KO improves endothelial function and reduces renal injury during diabetes. Additionally, our data also suggest that activation of HO-1 contributes to improved renal injury in diabetic Ephx2 KO mice.

Full Text available with Trip Pro

2011 American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

190. Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats (PubMed)

Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive rats We hypothesized that perinatal inhibition of soluble epoxide hydrolase (SEH), which metabolizes epoxyeicosatrienoic acids in the arachidonic acid (AA) cascade, with an orally active SEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), would persistently reduce blood pressure (BP) in adult SHR despite discontinuation of AUDA at 4 wk of age. Renal cytoplasmic

Full Text available with Trip Pro

2011 American Journal of Physiology - Endocrinology And Metabolism

191. Increases in plasma trans-EETs and blood pressure reduction in spontaneously hypertensive rats (PubMed)

activity, a deficiency of trans-EETs in the SHR was hypothesized to increase blood pressure (BP). This prediction was fulfilled, since sEH inhibition with cis-4-[4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid (AUCB; 2 mg·kg(-1)·day(-1) for 7 days) in the SHR reduced mean BP from 176 ± 8 to 153 ± 5 mmHg (P < 0.05), whereas BP in the control Wistar-Kyoto rat (WKY) was unaffected. Plasma levels of EETs in the SHR were lower than in the age-matched control WKY (16.4 ± 1.6 vs. 26.1 ± 1.8 ng/ml; P

Full Text available with Trip Pro

2011 American Journal of Physiology - Heart and Circulatory Physiology

192. Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats (PubMed)

-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid (c-AUCB) and HET-0016, the inhibitor of 20-HETE production, to study the role of EETs and 20-HETE in the regulation of renal function. Chronic c-AUCB treatment significantly decreased systolic blood pressure (SBP) (133 ± 1 vs. 163 ± 3 mmHg) and increased sodium excretion (1.23 ± 0.10 vs. 0.59 ± 0.03 mmol/day) in 2K1C rats. HET-0016 did not affect SBP and sodium excretion. In acute experiments, renal blood flow (RBF) was decreased in 2K1C rats

Full Text available with Trip Pro

2011 American Journal of Physiology - Regulatory, Integrative and Comparative Physiology

193. Soluble epoxide hydrolase inhibition prevents coronary endothelial dysfunction in mice with renovascular hypertension. (PubMed)

of the EET-synthesizing enzymes cytochrome P450 epoxygenases, fluconazole and N-methylsulfonyl-6-(2-propargyloxyphenyl)-hexanamide (MSPPOH), reduced the coronary relaxations to acetylcholine in control but not in 2K1C mice. The sEH expression was increased in 2K1C mice. The sEH inhibitor 12-(3-adamantan-1-yl-ureido)dodecanoic acid administered for 2 weeks starting 5 weeks after surgery in 2K1C mice (25 mg/l in drinking water) reduced aortic pressures and cardiac hypertrophy, improved the coronary

2011 Journal of Hypertension

194. Effect of a high-fat meal on the pharmacokinetics of saxagliptin in healthy subjects. (PubMed)

eng Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't 2010 02 11 England J Clin Pharmacol 0366372 0091-2700 0 Dietary Fats 0 Dipeptides 0 Dipeptidyl-Peptidase IV Inhibitors 9GB927LAJW saxagliptin PJY633525U Adamantane IM Adamantane analogs & derivatives blood pharmacokinetics Adult Area Under Curve Cross-Over Studies Dietary Fats Dipeptides blood pharmacokinetics Dipeptidyl-Peptidase IV Inhibitors blood pharmacokinetics Female Food-Drug Interactions Humans Male 2010 2 13

2011 Journal of clinical pharmacology Controlled trial quality: uncertain

195. [Ladasten in the management of non-motor symptoms of Parkinson's disease]. (PubMed)

-bromophenylamine PJY633525U Adamantane IM Adamantane analogs & derivatives therapeutic use Aged Female Humans Male Middle Aged Parkinson Disease drug therapy physiopathology Treatment Outcome 2011 3 26 6 0 2011 3 26 6 0 2011 4 6 6 0 ppublish 21434470

2011 Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova Controlled trial quality: uncertain

196. Aminoadamantane-resistant strains of influenza A2 virus (PubMed)

-adamantane methylamine and 2-adamantanamine sulphate. No aminoadamantane-resistant viruses were detected after passage of influenza four times in mice treated with lower (15 or 1.5 mg./kg./day) concentrations of aminoadamantane. Aminoadamantane had no detectable effect on the development of lung lesions in mice infected with the drug-resistant influenza strain, whereas lung lesions were reduced in aminoadamantane treated mice infected with a control strain of influenza A2/Singapore virus. No differences

Full Text available with Trip Pro

1973 The Journal of hygiene

197. Influenza

; however, no other data clearly show that treatment of influenza prevents complications. Peramivir is given IV as a single dose and can be used in patients > 2 yr who cannot tolerate oral or inhaled drugs. Studies of its use for influenza B are limited. Adamantanes ( amantadine and rimantadine ) were previously used; however, more than 99% of current and recent circulating influenza viruses are resistant to adamantanes, so these drugs are currently not recommended for treatment. Adamantanes block

2013 Merck Manual (19th Edition)

198. Quetiapine

( , , , , , ) ( , ) Agonists: Antagonists: (e.g., , , , , ) (e.g., , , , ) (e.g., , , , ) (e.g., , , ) (e.g., , , , , ) (e.g., , , , ) Agonists: Antagonists: (e.g., , , , , , , , ) (e.g., , , , ) (e.g., , , , ) Agonists: Antagonists: Agonists Benzazepines : Ergolines : Dihydrexidine derivatives : Phenethylamines : Others : Antagonists Typical antipsychotics : ( ) ( ) ( ) Atypical antipsychotics : (+ ) Others : Agonists Adamantanes : Aminotetralins : Ergolines : Dihydrexidine derivatives : Phenethylamines : Atypical

2012 Wikipedia

199. Doxepin

: Others : Antagonists Typical antipsychotics : ( ) ( ) ( ) Atypical antipsychotics : (+ ) Others : Agonists Adamantanes : Aminotetralins : Ergolines : Dihydrexidine derivatives : Phenethylamines : Atypical antipsychotics : ( ) Others : Antagonists Typical antipsychotics : ( ) ( ) ( ) Atypical antipsychotics : ( ) Antiemetics/gastroprokinetics/sedatives : Antidepressants : Others : See also: Agonists: Antagonists: First-generation: Second/third-generation: Others: (e.g., , , , , , , , , , , , ) (e.g

2012 Wikipedia

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>